Breathe Well Live Well
|
Phase II Data On Reslizumab Suggest Compound Improves Asthma Control And Lung …
Medical News Today (press release) Phase II data presented on a new investigational compound called reslizumab suggest a trend toward improvement in asthma control associated with a … |
View full post on asthma – Google News
|
Teva Highlights QNAZE(TM) HFA Phase III Data at the 2010 Annual Meeting of the …
MarketWatch (press release) The results, presented at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Phoenix, Ariz., showed that the … |
View full post on asthma – Google News
|
Lotus Pharmaceuticals, Inc. (LTUS) Receives Phase I Approval for Asthma Drug
International Business Times Lotus Pharmaceuticals, Inc. said that research conducted by a third party indicated that the Asthma market in China is approximately $300 million annually, … Lotus Pharmaceuticals Receives SFDA Approval to Initiate Phase I Clinical … |
View full post on asthma – Google News
|
Lotus Pharmaceuticals Receives SFDA Approval to Initiate Phase I Clinical …
PR Newswire (press release) According to IMS Health, a pharmaceutical market research firm, the anti-asthma and chronic obstructive pulmonary disease market in China reached … |
View full post on asthma – Google News
Condition: Asthma
Interventions: Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: AMG 853; Drug: Placebo
Sponsor: Amgen
Active, not recruiting – verified October 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Condition: Rhinovirus
Interventions: Drug: BTA798; Drug: Placebo
Sponsor: Biota Scientific Management Pty Ltd
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
Condition: Asthma
Interventions: Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo; Biological: CNTO 3157 or placebo
Sponsor: Centocor, Inc.
Recruiting – verified September 2010
View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days
|
Clinical Data, Inc. Presents Data from Phase I Studies of Stedivaze(TM …
MarketWatch (press release) Currently available adenosine agonists must be used with caution or are contraindicated in patients with asthma and COPD. The findings, presented at the … Clinical Data Reveals Positive Results From Early-stage Trials Of Stedivaze … |
View full post on asthma – Google News
|
GSK and Theravance announce combination ICS/LABA Phase II results in the …
MarketWatch (press release) Our ongoing collaboration with GSK includes the Phase III programmes in both COPD and asthma, which are already underway for Relovair and its components. … Theravance Announces Results From Phase II Study For Developmental Combination … |
View full post on asthma – Google News
National Institutes of Health researchers have shown that women’s cholesterol levels correspond with monthly changes in estrogen levels. This natural variation, they suggest, might indicate a need to take into account the phases of a woman’s monthly cycle before evaluating her cholesterol measures. On average, the total cholesterol level of the women in the study varied 19 percent over the course of the menstrual cycle.
View full post on National Institutes of Health (NIH) News Releases